Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.91

€0.91

-0.440%
-0.004
-0.440%
-
 
12.12.25 / Stuttgart Stock Exchange WKN: A0M4VZ / Name: Launch / Stock / Machinery, Equipment & Components / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for Launch

sharewise wants to provide you with the best news and tools for Launch, so we directly link to the best financial data sources.

News

Rocket Lab Stock Jumps After Earnings, Despite Neutron Delay: https://www.marketbeat.com/logos/articles/med_20251111123555_rocket-lab-stock-jumps-after-earnings-despite-neut.jpg
Rocket Lab Stock Jumps After Earnings, Despite Neutron Delay

Rocket Lab USA (NASDAQ: RKLB) delivered a strong third quarter, and the market wasted no time responding. Shares climbed in after-hours trading after the company posted record revenue, showing

Rocket Lab Stock Dips 14%—Buying Opportunity Ahead?: https://www.marketbeat.com/logos/articles/med_20251029115902_rocket-lab-stock-dips-14buying-opportunity-ahead.jpg
Rocket Lab Stock Dips 14%—Buying Opportunity Ahead?

After a decisive breakout through resistance near $55, shares of Rocket Lab USA (NASDAQ: RKLB) have finally taken a breather. With the company set to report earnings in November, investors might

Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead: https://www.marketbeat.com/logos/articles/med_20251014132433_novo-nordisks-akero-buy-targets-eli-lillys-lead.jpg
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead

Novo Nordisk A/S (NYSE: NVO) recently announced plans to acquire Akero Therapeutics. The deal, which is valued at around $4.7 billion, is scheduled to close early in 2026. After initially moving

Big Gains Alert: These 3 Tech Stocks Are Surging This Month: https://www.marketbeat.com/logos/articles/med_20251008180338_big-gains-alert-these-3-tech-stocks-are-surging-th.jpg
Big Gains Alert: These 3 Tech Stocks Are Surging This Month

Many investors allocate a portion of their portfolio to stock picking and trading strategies. One popular tactic is tracking stocks with the highest percentage gains, as these moves often signal

Rocket Lab: A Space Giant Hitting New Highs—Time to Chase?: https://www.marketbeat.com/logos/articles/med_20251008104222_rocket-lab-a-space-giant-hitting-new-highstime-to.jpg
Rocket Lab: A Space Giant Hitting New Highs—Time to Chase?

Rocket Lab USA (NASDAQ: RKLB) has gone from strength to strength over the past year, cementing its position as one of the most dominant players in the space launch and infrastructure industry

Rocket Lab's Electron: The Quiet Workhorse Powering Momentum: https://www.marketbeat.com/logos/articles/med_20251001104756_rocket-labs-electron-the-quiet-workhorse-powering.jpg
Rocket Lab's Electron: The Quiet Workhorse Powering Momentum

For months, Rocket Lab USA (NASDAQ: RKLB) has been stuck in a broad base, consolidating between $40 and $55. While breakout attempts have been met with resistance, most recently capped by a $750

AppLovin Stock Momentum Builds With $800+ Analyst Price Target: https://www.marketbeat.com/logos/articles/med_20250929162654_applovin-stock-momentum-builds-with-800-analyst-pr.png
AppLovin Stock Momentum Builds With $800+ Analyst Price Target

Over the past 52 weeks, ad-tech stock AppLovin (NASDAQ: APP) has been among the biggest standouts in the market. Year-to-date, shares are up by a staggering 457%. That performance ranks in the

Rocket Lab Strengthens Case for Breakout With New Launch Pad
Rocket Lab Strengthens Case for Breakout With New Launch Pad

There’s simply no slowing down the rise of Rocket Lab USA, Inc. (NASDAQ: RKLB). After a brief pullback from its 52-week high, shares of the aerospace and defense company tested support near $40

Rocket Lab Reports Next Week: Here’s What Investors Should Know
Rocket Lab Reports Next Week: Here’s What Investors Should Know

Rocket Lab USA, Inc. (NASDAQ: RKLB), a leading aerospace name, is set to report earnings for the second quarter of fiscal 2025 on August 7, and institutional and retail investors are watching

D-Wave, SuperQ, and Verge: A New Path Forward for Quantum?
D-Wave, SuperQ, and Verge: A New Path Forward for Quantum?

Finally breaking above $20 per share in mid-July, quantum computing giant D-Wave Quantum Inc. (NYSE: QBTS) extended its rally as it touched new all-time highs. As shares have nearly doubled in

Rocket Lab: Latest Catalysts Bolster the Bull Case
Rocket Lab: Latest Catalysts Bolster the Bull Case

Rocket Lab USA (NASDAQ: RKLB) continues to defy expectations. While the broader market grapples with macroeconomic uncertainty and rising volatility, this vertically integrated space and defense

Rocket Lab: Europe Comes Calling as Momentum Builds
Rocket Lab: Europe Comes Calling as Momentum Builds

The positive news flow continues for aerospace and defense company Rocket Lab USA (NASDAQ: RKLB). Previously, it was a significant analyst boost when Cantor Fitzgerald increased its price target

SpaceX Changed the Economics of Spaceflight. Now It's Doing the Same Thing to Satellite Cost.: https://g.foolcdn.com/editorial/images/842085/earth-orbit-crowded-will-all-sorts-and-manner-of-satellites.jpg
SpaceX Changed the Economics of Spaceflight. Now It's Doing the Same Thing to Satellite Cost.

The third time was the charm.

Twice in the past week, United Launch Alliance (ULA) had to "scrub" attempts to launch a new ViaSat-3 F2 communications satellite for customer Viasat (NASDAQ: VSAT)